Overview

A Clinical Trial of Infliximab for Uveitis

Status:
Completed

Trial end date:
2006-12-01

Target enrollment:

Participant gender:

Summary

This project is designed to test the hypothesis that inhibition of binding between tumor necrosis factor alpha (TNF-alpha) and its receptors using Remicade (infliximab, chimeric mouse/human IgG1K monoclonal antibody directed against human TNF-alpha, Centocor, Malvern,PA) is clinically useful for patients with uveitis that is refractory to other forms of systemic immunosuppressive therapy.

Phase:

N/A

Details

Lead Sponsor:

Oregon Health and Science University

Collaborator:

Centocor, Inc.

Treatments:

Infliximab